AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

Over the weekend, a Texas aerospace company made history with the first successful landing on the moon by a private firm.

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2024 investor letter. A ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time, the ...

Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.